Protagonist Therapeutics Inc (NASDAQ:PTGX) insider David Y. Liu sold 3,500 shares of the firm’s stock in a transaction dated Monday, March 12th. The shares were sold at an average price of $21.29, for a total value of $74,515.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Protagonist Therapeutics Inc (NASDAQ PTGX) opened at $20.75 on Wednesday. Protagonist Therapeutics Inc has a 52 week low of $8.00 and a 52 week high of $23.97.
Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings data on Wednesday, March 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.19. The company had revenue of $11.28 million during the quarter, compared to analysts’ expectations of $8.75 million. equities research analysts forecast that Protagonist Therapeutics Inc will post -1.3 EPS for the current fiscal year.
A number of brokerages recently commented on PTGX. Zacks Investment Research cut Protagonist Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 4th. BidaskClub upgraded Protagonist Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 3rd. BMO Capital Markets restated an “outperform” rating and set a $42.00 target price (down from $44.00) on shares of Protagonist Therapeutics in a report on Thursday, March 8th. Finally, Stifel Nicolaus began coverage on Protagonist Therapeutics in a report on Monday, January 29th. They set a “buy” rating and a $32.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $34.00.
Protagonist Therapeutics Company Profile
Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.